Коморбидный пациент с бронхолегочной патологией: фокус на нарушения микроциркуляции

Коморбидный пациент с бронхолегочной патологией: фокус на нарушения микроциркуляции. Consilium Medicum. 2020; 22 (12): 93–96. DOI: 10.26442/20751753.2020.12.200526

________________________________________________

Comorbid patient with bronchopulmonary pathology: focus on microcirculation disorders. Consilium Medicum. 2020; 22 (12): 93–96. DOI: 10.26442/20751753.2020.12.200526

Читать PDF

Аннотация

Болезни органов дыхания занимают ведущие позиции в мире по распространенности и смертности, характеризуются высокой степенью коморбидности, что создает определенные сложности в их диагностике и лечении. Объединяющим звеном патогенеза респираторных заболеваний и сопутствующей патологии являются микроциркуляторные нарушения. Именно этой проблеме посвящен симпозиум «Коморбидный пациент с бронхолегочной патологией: фокус на нарушения микроциркуляции», проведенный в рамках XXX Национального конгресса по болезням органов дыхания (27–30 октября), который прошел в онлайн-режиме. На симпозиуме с докладами выступили ведущие пульмонологи России: профессор В.И. Трофимов (Санкт-Петербург), профессор И.И. Несторович (Санкт-Петербург), сотрудник кафедры общей врачебной практики ФГБОУ ВО «Первый СПб ГМУ им. акад. И.П. Павлова» О.А. Лазовская (Санкт-Петербург), врач-терапевт Стационарного отделения скорой медицинской помощи НИИ хирургии и неотложной медицины ФГБОУ ВО «Первый СПб ГМУ им. акад. И.П. Павлова» А.А. Лебедева (Санкт-Петербург).

Ключевые слова: респираторные заболевания, нарушения микроциркуляции, эндотелиальная дисфункция

________________________________________________

Respiratory diseases are highly prevalent, represent one of the leading causes of mortality worldwide and are characterized by high levels of comorbidity, which all creates certain difficulties for their diagnosis and treatment. The common link in pathogenesis of respiratory diseases and concomitant pathologies are microcirculatory disorders. It was that issue the symposium "Comorbid Patient with Bronchopulmonary Pathology: Focus on Microcirculation Disorders" was dedicated to. It was held within the framework of online XXX National Congress on Respiratory Diseases (October 27–30). Leading pulmonologists of Russia made presentations at the symposium: Professor V.I. Trofimov (St. Petersburg), professor I.I. Nestorovich (St. Petersburg), employee of the Department of General Medical Practice of the FSBEI of HE “acad. I.P. Pavlova First St Petersburg SMU" O. A. Lazovskaya (St. Petersburg), employee of the Inpatient Emergency Department of the Research Institute of Surgery and Emergency Medicine of the FSBEI of HE “acad. I.P. Pavlova First St Petersburg SMU" A.A. Lebedeva (St. Petersburg).

Key words: respiratory diseases, microcirculation disorders, endothelial dysfunction.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. GBD 2015 Chronic Respiratory Disease Collaborators. https://www.who.int/gho/mortality_burden_disease/causes_death/top_10/en/
2. Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med 2010; 7 (3): e1000220.
3. Eickhoff P, Valipour A, Kiss D et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178 (12): 1211–8.
4. Shimbo D, Grahame-Clarke C, Miyake Y et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 2007; 192 (1): 197–203.
5. Власов Т.Д., Петрищев Н.Н., Лазовская О.A. Дисфункция эндотелия. Правильно ли мы понимаем этот термин? Вестник анестезиологии и реаниматологии. 2020; 17 (2): 76–84. DOI: 10.21292/2078-5658-2020-17-2-76-84
[Vlasov T.D., Petrischev N.N., Lazovskaya O.A. Endothelial dysfunction. Do we understand this term properly? Messenger of Anesthesiology and Resuscitation. 2020; 17 (2): 76–84. DOI: 10.21292/2078-5658-2020-17-2-76-84 (in Russian).]
6. Lesser BA, Leeper KV Jr., Stein PD et al. The diagnosis of acute pulmonary embolism in patients with chronic obstructive pulmonary disease. Chest 1992; 102 (1): 17–22.
7. Mispelaere D, Glerant JC, Audebert M et al. Pulmonary embolism and sibilant types of chronic obstructive pulmonary disease decompensations. Rev Mal Respir 2002; 19 (4): 415–23.
8. Tillie-Leblond I, Mastora I, Radenne F et al. Risk of Pulmonary Embolism after a Negative Spiral CT Angiogram in Patients with Pulmonary Disease: 1-year Clinical Follow-up Study. Radiology 2002; 223 (2): 461–7.
9. Sprunger DB, Olson AL, Huie TJ et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J 2012; 39 (1): 125–32.
10. Cavaillès A, Brinchault-Rabin G, Dixmier A et al. Comorbidities of COPD. Eur Respir Rev 2013; 22 (130): 454–75.
11. Золотницкая В.П., Титова О.Н., Лукина О.В., Бобров Е.И. Тромбоэмболия легочной артерии в сочетании с обратимой и необратимой бронхиальной обструкцией. Регионарное кровообращение и микроциркуляция. 2017; 16 (1): 27–32. DOI: 10.24884/1682-6655-2017-16-1-27-31
[Zolotnitskaya V.P., Titova O.N., Lukina O.V., Bobrov E.I. Pulmonary embolism in combination with a reversible and irreversible airflow obstruction. Regional blood circulation and microcirculation. 2017; 16 (1): 27–31. DOI: 10.24884/1682-6655-2017-16-1-27-31 (in Russian).]
12. Верткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность. Клиническая медицина. 2012; 90 (10): 4–11.
[Vertkin A.L., Rumyantsev M.A., Skotnikov A.S. Comorbidity. Clinical Medicine. 2012; 90 (10): 4–11 (in Russian).]
13. Middeldorp S, Coppens M, van Haaps TF et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (8): 1995–2002.
14. Zhang L, Yan X, Fan Q et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020; 18 (6): 1324–29.
15. Анаев Э.Х., Княжеская Н.П. Коагулопатия при Covid-19: фокус на антикоагулянтную терапию. Практическая пульмонология. 2020; 1: 3–13.
[Anaev E.Kh., Knyazheskaya N.P. Coagulopathy in Covid-19: focus on anticoagulant therapy. Prakticheskaia Pul'monologiia. 2020; 1: 3–13 (in Russian).]
16. Gerlag DM, Raza K, van Baarsen LG et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012; 71 (5): 638–41.
17. Насонов Е.Л. Ревматология. Российские клинические рекомендации. 2019.
[Nasonov E.L. Rheumatology. Russian clinical guidelines. 2019 (in Russian).]
18. Александрова Е.Н., Насонов Е.Л. Инновационные технологии в лабораторной диагностике ревматических заболеваний. Научно-практическая ревматология. 2010; 48 (2): 13–20. DOI: 10.14412/1995-4484-2010-1411
[Aleksandrova E.N., Nasonov E.L. Innovative technologies in the laboratory diagnosis of rheumatic diseases. Rheumatology Science and Practice. 2010; 48 (2): 13–20. DOI: 10.14412/1995-4484-2010-1411 (in Russian).]
19. Giles JT, Danoff SK, Sokolove J et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014; 73 (8): 1487–94.
20. Zhu J, Zhou Y, Chen X, Li J. A meta-analysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol 2014; 41 (7): 1282–9.
21. Бестаев Д.В., Амирджанова В.Н., Насонов Е.Л. Исследование качества жизни больных с интерстициальным поражением легких при ревматоидном артрите. Владикавказский медико-биологический вестник. 2014; 19 (28): 8–13.
[Bestaev D.V., Amirdzhanova V.N., Nasonov E.L. Issledovanie kachestva zhizni bol'nykh s interstitsial'nym porazheniem legkikh pri revmatoidnom artrite. Vladikavkazskii mediko-biologicheskii vestnik. 2014; 19 (28): 8–13 (in Russian).]
22. Olson AL, Swigris JJ, Sprunger DB et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183 (3): 372–8.
23. Demoruelle MK, Solomon JJ, Fischer A et al. The lung may play a role in the pathogenesis of rheumatoid arthritis. Int J Clin Rheumtol 2014; 9 (3): 295–309.
24. Gonzalez E, Moore EE, Moore HB et al. Syndecan-1 a Marker of Endothelial Injury is Associated with Increased Blood Product Requirement and Poor Outcomes in Trauma Patients. J Surgic Res 2014; 186 (2): 588–9.
25. Torres Filho IP, Torres LN, Salgado C et al. Plasma syndecan-1 and heparan sulfate correlate with microvascular glycocalyx degradation in hemorrhaged rats after different resuscitation fluids. Am J Physiol Heart Circ Physiol. 2016; 310 (11): H1468–78.

________________________________________________

1. GBD 2015 Chronic Respiratory Disease Collaborators. https://www.who.int/gho/mortality_burden_disease/causes_death/top_10/en/
2. Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med 2010; 7 (3): e1000220.
3. Eickhoff P, Valipour A, Kiss D et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178 (12): 1211–8.
4. Shimbo D, Grahame-Clarke C, Miyake Y et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 2007; 192 (1): 197–203.
5. Vlasov T.D., Petrischev N.N., Lazovskaya O.A. Endothelial dysfunction. Do we understand this term properly? Messenger of Anesthesiology and Resuscitation. 2020; 17 (2): 76–84. DOI: 10.21292/2078-5658-2020-17-2-76-84 (in Russian).
6. Lesser BA, Leeper KV Jr., Stein PD et al. The diagnosis of acute pulmonary embolism in patients with chronic obstructive pulmonary disease. Chest 1992; 102 (1): 17–22.
7. Mispelaere D, Glerant JC, Audebert M et al. Pulmonary embolism and sibilant types of chronic obstructive pulmonary disease decompensations. Rev Mal Respir 2002; 19 (4): 415–23.
8. Tillie-Leblond I, Mastora I, Radenne F et al. Risk of Pulmonary Embolism after a Negative Spiral CT Angiogram in Patients with Pulmonary Disease: 1-year Clinical Follow-up Study. Radiology 2002; 223 (2): 461–7.
9. Sprunger DB, Olson AL, Huie TJ et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J 2012; 39 (1): 125–32.
10. Cavaillès A, Brinchault-Rabin G, Dixmier A et al. Comorbidities of COPD. Eur Respir Rev 2013; 22 (130): 454–75.
11. Zolotnitskaya V.P., Titova O.N., Lukina O.V., Bobrov E.I. Pulmonary embolism in combination with a reversible and irreversible airflow obstruction. Regional blood circulation and microcirculation. 2017; 16 (1): 27–31. DOI: 10.24884/1682-6655-2017-16-1-27-31 (in Russian).
12. Vertkin A.L., Rumyantsev M.A., Skotnikov A.S. Comorbidity. Clinical Medicine. 2012; 90 (10): 4–11 (in Russian).
13. Middeldorp S, Coppens M, van Haaps TF et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (8): 1995–2002.
14. Zhang L, Yan X, Fan Q et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020; 18 (6): 1324–29.
15. Anaev E.Kh., Knyazheskaya N.P. Coagulopathy in Covid-19: focus on anticoagulant therapy. Prakticheskaia Pul'monologiia. 2020; 1: 3–13 (in Russian).
16. Gerlag DM, Raza K, van Baarsen LG et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012; 71 (5): 638–41.
17. Nasonov E.L. Rheumatology. Russian clinical guidelines. 2019 (in Russian).
18. Aleksandrova E.N., Nasonov E.L. Innovative technologies in the laboratory diagnosis of rheumatic diseases. Rheumatology Science and Practice. 2010; 48 (2): 13–20. DOI: 10.14412/1995-4484-2010-1411 (in Russian).
19. Giles JT, Danoff SK, Sokolove J et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014; 73 (8): 1487–94.
20. Zhu J, Zhou Y, Chen X, Li J. A meta-analysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol 2014; 41 (7): 1282–9.
21. Bestaev D.V., Amirdzhanova V.N., Nasonov E.L. Issledovanie kachestva zhizni bol'nykh s interstitsial'nym porazheniem legkikh pri revmatoidnom artrite. Vladikavkazskii mediko-biologicheskii vestnik. 2014; 19 (28): 8–13 (in Russian).
22. Olson AL, Swigris JJ, Sprunger DB et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183 (3): 372–8.
23. Demoruelle MK, Solomon JJ, Fischer A et al. The lung may play a role in the pathogenesis of rheumatoid arthritis. Int J Clin Rheumtol 2014; 9 (3): 295–309.
24. Gonzalez E, Moore EE, Moore HB et al. Syndecan-1 a Marker of Endothelial Injury is Associated with Increased Blood Product Requirement and Poor Outcomes in Trauma Patients. J Surgic Res 2014; 186 (2): 588–9.
25. Torres Filho IP, Torres LN, Salgado C et al. Plasma syndecan-1 and heparan sulfate correlate with microvascular glycocalyx degradation in hemorrhaged rats after different resuscitation fluids. Am J Physiol Heart Circ Physiol. 2016; 310 (11): H1468–78.

Авторы

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.